The UK Commission on Human Medicines (CHM) has tightened its guidance on Valneva SE’s single‑dose chikungunya vaccine IXCHIQ, limiting use to adults aged 18‑59 who are at risk of infection and do not have contraindicated medical conditions. The update, issued on February 13, 2026, follows a temporary pause by the MHRA in June 2025 that restricted the vaccine for people aged 65 and older pending a safety review.
The new restrictions come after serious adverse events were reported during a La Réunion outbreak campaign in 2025, where elderly recipients with underlying health conditions experienced severe reactions. The UK decision mirrors the U.S. Food and Drug Administration’s August 2025 suspension of IXCHIQ’s license, which was followed by Valneva’s withdrawal of its U.S. Biologics License Application and Investigational New Drug application in January 2026.
Under the updated UK guidance, IXCHIQ is contraindicated for individuals with immunodeficiency or immunosuppression, hypertension, cardiovascular disease, diabetes mellitus, or chronic kidney disease. The vaccine must also be administered at least 30 days before travel to ensure that any serious adverse reactions occur while the individual is in the UK, a measure designed to protect travelers and reduce post‑marketing risk.
Valneva’s financials underscore the commercial impact of the new restrictions. The company reported €169.6 million in total revenue for 2024, with product sales of €163.3 million, and €127.0 million in revenue for the first nine months of 2025. IXCHIQ has historically been a significant contributor to Valneva’s product portfolio, and the UK market represents a sizable share of its potential sales. Management has stated that it will continue monitoring post‑marketing safety data and work with authorities on any further adjustments, but the tightening of UK guidance signals a broader regulatory trend that could constrain future growth.
The UK update is part of a pattern of increasing scrutiny across major markets. With the U.S. FDA’s suspension and the MHRA’s earlier pause, regulators are prioritizing safety over broader access, especially for older adults and those with comorbidities. For Valneva, the cumulative effect of these actions may erode confidence among clinicians and patients, reduce market penetration, and pressure the company to invest in additional safety studies or alternative indications to sustain its commercial trajectory.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.